pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-155 |
Genomic Coordinates | chr21: 25573980 - 25574044 |
Description | Homo sapiens miR-155 stem-loop |
Comment | Human mir-155 is predicted based on homology to a cloned miR from mouse (MIR:MI0000177) . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-155-3p | ||||||||||||||||||
Sequence | 43| CUCCUACAUAUUAGCAUUAACA |64 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MYO6 | ||||||||||||||||||||
Synonyms | DFNA22, DFNB37, Myo6-007, Myo6-008 | ||||||||||||||||||||
Description | myosin VI | ||||||||||||||||||||
Transcript | NM_004999 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MYO6 | |||||||||||||||||||||
3'UTR of MYO6 (miRNA target sites are highlighted) |
>MYO6|NM_004999|3'UTR 1 ATGTTGCACACCAGCCTTACAGCTGGGAGCCTTTGCCATGGTACTTAGGTAGGGTGTGTGCCCCCAGATTTAACCATTCC 81 ATAATCATGTTAGAGTTACTTCTATAAAGTGAACAGATTTTATTAATCACGGCTTTTGGTGAATTTGTTTAAGGTTAATT 161 ATGGTAGCAAATTTTGGACCTAAACATTATTTTTCTGTATCCCGCTGTAATTCCCAAAACTCTCATTATTCTCTAACTAT 241 TACACATGGGCATATTCTGATGTTTCTCATCCTTTGCCAGAAGACTACCTTACATCCATCGTAATTGTTCTCTAGGAAAA 321 GAGAACTTTTTTCAAAATTCAAAATACTTTTTAAGGATGGCACAGTACCATATAACTGGAGTAATAAAACATGAGCTTAC 401 ATTCTTACAATAACTAAACCACTTAAAATGATCAAGGCACTAATGTTTTGGTCTGAAAAGCTGTGTACTTTATAGACATT 481 TTCAGACATTTTTGGAAATTTCCATTAAAGGTGGAAAATCTATTTTTTTCCTCCTTTGCAGTGTCTTAGTTTGAATGAAA 561 CACTTCGAAGTTCTAGAATTCTAGAAAGAGCCTTAATGTATTTGATGTATTCTGTGATAAGAGGTACTAATAGTATCCAG 641 CACAGATTTGCTTTTCTTTGCTAGCACAATGTGTGTTGCTGTCAGAATATTCTTTTTATATTCTGTGGAAAAATAAAGGA 721 AATTCAGATTGTTTAAATGCCTAAAAGTTTTGAGATAAGTTTTGTTTCAATTAGAAAAGGAAATAGGTTTTAGGTGGCAT 801 AGTGGCTTAACTGGACTGAATTCAAATATTCTTTCAACTTCATCTCAATAGTGATTTTTGTATCAGAATCTTGTCCAAGT 881 TGTTTCATTGATTTAGTAAGTGTTCTGCTTCCAACATCTTTCTTTTTAAGAAATTCCTAGTGTCTTTTTTGGCCTTTGAG 961 GTTTTGGTAATTGTAGACCTGTTTCATAAGCTTTGTAATTCAGAAATCCTTGTATTTAGTAAGTGCTTGTTTTACATAAC 1041 TGATAATTTTAAAATGTTTTCTTTGTGTGCTGTTAGTATTGATTCAAATGTCAGCAGCTTTAAGCCTAATATTTATGACT 1121 TTCACATTTGGAATTTAAAGACAAAAATACATCAAGGAGTTATGCTGACATAATTCTAAGGAGTTTTGTTGTATTTTAGA 1201 ATAAAATTATAAAGTAAAATGATTCTCTGTACTGCTTTTTCCCCCAGTTTTTAGAGACCCTAACCTTTGAAATGAAATTC 1281 CAGTGATTTCTTTTTTCCCTAGAAAGATTACCTCAGTTAGGGAAGTATTTCCCAGCTGACTAGTGTTTGTGAGCCACAGA 1361 CACTGTCTTCAGAATTGCTTCTCTCATGTCTTAGTAGAGAAATATTTATTTATTATGATACATTCAAATGATTGTCAAGT 1441 TAAATTAAATGGTTGTGTCTGTGCTATTGAGAATGCAAATGTGATTATCTTTTGAAGGCTGTATTACTGCATAGCTTCAC 1521 CCACCCTCGGGTCATTTCGTCCCTGTGATTGGGGACAGAAGGTGTAGCTACTGAAGTAAATGACCTATTCTCTCTCTTCC 1601 ATCTCTCGCCTTTAACTGGTGTTTTTATTTGTGTAGGATAGTGAATGATAAGCTTTTTTCCTAACCAGTAGTGAGTAAAG 1681 TTCTTGAACAAAATTTAGTAGCCAAATTGTTTTTTAATGACATGTCTCTTTAGTACAATAGTTTTGTGTATCTTTTAGAT 1761 ACATTAATAGGCACTAGATGGAAAATTAAAGAGTTAAACATATTTAAATGAGAGAATCTAATGTTTCAGAAATTTGTAAG 1841 AAATGTATCACAGCAAAGGGTTGTTATAAGTCCTTAGTTTTTGACTCTAATAGTTAATACAATTATAGTTAATCTTAAGC 1921 CATAATGTTTCTAATCATGTCACACAGCTGTCCTAGAACTTATCTATTTAAAATAGTTTCCTGAGTTAATTTTGGCCAGC 2001 AGGGCAACTGCCCTAATTCAGATAGATTTACAGTAACCTACGTACAGTAGATGCACATACACACAGACACCCCTTTGCTG 2081 GAGAAACTTAGGACCCTGTCAGCCTTTTAAAGGAAACAGCAGGAGTGGTGTCCTAAATGATGTTCATGCAGCTGCTTTAC 2161 CATGTTCACAGTCAAGCCCATGCATGCCAGGTTAAAACTGTGGAAATCAAAAGTAAATTCACTCATATTTTAATCATTTT 2241 AACTGAGATTTAAAATTAGAAGTTTAAACCACTATATATAAAGAACTAATCTTTTCTTAATACCAGTTCTTTCCATAGCA 2321 TATGCTTTGCAAAGGCAGCATGCATAAAATATTTAAAATGAGAGGACAGAATGTTTTCACATTTGATTCAATTTTAATAT 2401 AATTCCTAATTGTGGTAACACAGTTGAGATATGTATTATGAGTTATGGGAACTAATTGAGAAAAGGAAGTTACTCTAATC 2481 CACGTATGTTAAGAGAATATTGAGTTTTCTTAGTTGTAAAGTTGGGGAGATGGCACCTTCTCAGAGGATTGTGAAAATAT 2561 GAGGAAGAAACAAAACAGTGCATGTAGGAGCACAGGGCCACACAAAGGCATTCTATTGTTATGCTCATTCTGCTTCTGTA 2641 ATGACTTTTCATAGGTCATTCTTGTGAACCATTTTGTTTTGCAAGCAACCAAGGAAAGAACATCTTAAGTGGAAAATCAG 2721 TGGTGGTTGTGAACACTTAGAGAATAGCAATCCACAGGCAAGAATAATGGTATTGTTTGTAGAGCTTTATTAATTGGATA 2801 TTTTTTAAAAGACATTTTCATTCACAGGTCATTACTATGGTTCTCAGCGATCCAAATATGTAGATCATTGGTTTTTTTTT 2881 TTACCTGAAGTAGCTTAAGAGTACTTGGATCAGTAGAATAAATATTTATTGAATCAATCAGTCAGCCAATTAATATGATG 2961 TTAGTGATAGACCTGCCTCCTTTTATGGAAGAGGTAACAGATCCAGAGAGGTCAAGTAATTTAGTTGTAGACTGAAAAAT 3041 ATATCAAAGCCTTTGCTGCAATCATATGTAACAAAAAGAACCAAAACAAACACTTTTTAGTGGCACCTGTGGATTTACAA 3121 AGGGTTGCCTCTCTGTCATTCCACAACTTCAGAAGGTGTGACAGGTTTTCCCTATTTATCATTACCAATAATAACAAGTA 3201 TTGAGAGTTTTAAAATTTCTCCCAGAAGATAAACTAACAAGGATGGAAGGGGAGGGCAAAGGATATCTAAACATGAGAAT 3281 AAGGACATGTTAGAGGGGGGGAAACAGTTGTAACAATAAGGAAAGAGAAGAGCAACAGTGGAAGAGACAGGTTGTGTGCC 3361 CCTAAAGATTCTGCACCCCCAGTTTGGAAACACTGATACATTTTAGGACACAGAGCACTCCTAGATCTCTACGAAATTTT 3441 AGAATGAATAATGTGTAATTTATAGGATCAGAACGTATGGTTATTAAAACTTGGATCAAGATATGCCCGGTGTATACATT 3521 CTTAGCACATAGGAATGGCACTGCCATACTGGAGAAGGTCAGCAGTAAATAGGCATTCTGTACATAAGCCTCATGGAAGG 3601 GTAAGATGGAGAGACTGGCAGAAGTAGCACCTACTCTGCTGGGAGCACTTCTCTGAGTACGCTTTAGTTCAATTCAAATC 3681 ACTGTATTCTTTCCCCATTGCTAACCTAATATATGAAACAAGCTTAGCTGTCTCAGAAGTTTTTCAAGAGATGATCAGGA 3761 AAAATTAATGCACATTCAAAAGGAGAATCTTCAGTACAAATTTGTTTTTTTAAAAATAGATTTAGGGCTGGGCGCGGTGG 3841 CTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCACGAGGTCAAGACTTCGAGACCAGCCTGGCCAA 3921 CATGGTGAAACCCTGTCTCTACTAAAAATACAAAACATTAGCCAGGCGTGGTAGTGGGTGCCTGTAATCCCTGCTACTTG 4001 GGAGGCTGAGGCAGGAGAATCACTTGAACGCGGGAGGCAGAGGTTGCAGGGAGCCGAGATGGCGCCATTGCACTCCATCC 4081 TGGGCAACAAGAGCGAAATTCCATCTCAAAAAATAAAATAGATTTAGGGGGTACAAGTGCAGTTTTGTTACATGGGTATA 4161 TTGCATAGTGGTAAAATGTGGGCTTTTAGTGTACCTAACACCCAGAGAAGCATACATTGTGCCCAGTAGGTAATTTTTCA 4241 TCCCTAAACCTTTTCTCAGCCTCCCACTTTCTGGAGTCTCCAATGTCGGTTATTCCACTCTTTATGTCCATATCTACACA 4321 TTCAATCCTAATTTGTACCAAGTAGCATCTCACCTTTAAATCACAGGCTTATTAGTTGGGTGTTTTCTTTTTACTTATGA 4401 AAATTCATCTAGTCAAACTGTCAATTAATTTTTCCTCATTTCATTAAAAGTGTATATCTAATGCTTTCTCTAAAAATTGA 4481 TGTACTGGAAATACAAATAAATAAATGCTCCCTGTGTAGAATTTC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 4646.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 4646.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065670. RNA binding protein: AGO2. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Prostate Tissue |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760639. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP-MDV_A
PAR-CLIP data was present in SRX1760583. RNA binding protein: AGO2. Condition:AGO-CLIP-LNCaP_A
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000369981.3 | 3UTR | UUUAUUUGUGUAGGAUAGUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1065670 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / 4-thiouridine, 3_ML_LG |
Location of target site | ENST00000369981.3 | 3UTR | UAUUUGUGUAGGAUAGU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
73 hsa-miR-155-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005808 | IRAK3 | interleukin 1 receptor associated kinase 3 | 4 | 1 | ||||||||
MIRT082844 | ZNF460 | zinc finger protein 460 | 2 | 4 | ||||||||
MIRT256047 | UBE2K | ubiquitin conjugating enzyme E2 K | 2 | 4 | ||||||||
MIRT437787 | PTEN | phosphatase and tensin homolog | 2 | 1 | ||||||||
MIRT456168 | ZDHHC6 | zinc finger DHHC-type containing 6 | 2 | 2 | ||||||||
MIRT464916 | TXNIP | thioredoxin interacting protein | 2 | 4 | ||||||||
MIRT475559 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 2 | 2 | ||||||||
MIRT499608 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | 2 | 8 | ||||||||
MIRT504220 | MYO6 | myosin VI | 2 | 4 | ||||||||
MIRT504256 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT507642 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT522858 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT527505 | MYD88 | myeloid differentiation primary response 88 | 5 | 2 | ||||||||
MIRT530713 | ORMDL3 | ORMDL sphingolipid biosynthesis regulator 3 | 2 | 2 | ||||||||
MIRT532851 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT535952 | MIA3 | MIA family member 3, ER export factor | 2 | 2 | ||||||||
MIRT539041 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT556391 | LUC7L | LUC7 like | 2 | 2 | ||||||||
MIRT558617 | CNOT6L | CCR4-NOT transcription complex subunit 6 like | 2 | 2 | ||||||||
MIRT559869 | ATXN3 | ataxin 3 | 2 | 2 | ||||||||
MIRT569208 | SHC3 | SHC adaptor protein 3 | 2 | 2 | ||||||||
MIRT573122 | C18orf25 | chromosome 18 open reading frame 25 | 2 | 2 | ||||||||
MIRT575076 | Ddit4 | DNA-damage-inducible transcript 4 | 2 | 2 | ||||||||
MIRT607597 | ABCF3 | ATP binding cassette subfamily F member 3 | 2 | 6 | ||||||||
MIRT609386 | PHEX | phosphate regulating endopeptidase homolog X-linked | 2 | 2 | ||||||||
MIRT610550 | MDN1 | midasin AAA ATPase 1 | 2 | 2 | ||||||||
MIRT612390 | TCF7L2 | transcription factor 7 like 2 | 2 | 2 | ||||||||
MIRT612910 | GTDC1 | glycosyltransferase like domain containing 1 | 2 | 6 | ||||||||
MIRT613314 | ARL5C | ADP ribosylation factor like GTPase 5C | 2 | 2 | ||||||||
MIRT613356 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 4 | ||||||||
MIRT613541 | CLMP | CXADR like membrane protein | 2 | 2 | ||||||||
MIRT617029 | SYT6 | synaptotagmin 6 | 2 | 2 | ||||||||
MIRT618044 | MRVI1 | murine retrovirus integration site 1 homolog | 2 | 2 | ||||||||
MIRT619307 | KIRREL | kirre like nephrin family adhesion molecule 1 | 2 | 2 | ||||||||
MIRT623209 | MTFR1L | mitochondrial fission regulator 1 like | 2 | 2 | ||||||||
MIRT625448 | RANGAP1 | Ran GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT634551 | MACC1 | MACC1, MET transcriptional regulator | 2 | 2 | ||||||||
MIRT640740 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT640906 | RAB13 | RAB13, member RAS oncogene family | 2 | 2 | ||||||||
MIRT644025 | ZNF792 | zinc finger protein 792 | 2 | 2 | ||||||||
MIRT651489 | WT1 | Wilms tumor 1 | 2 | 2 | ||||||||
MIRT652037 | LINC00598 | long intergenic non-protein coding RNA 598 | 2 | 2 | ||||||||
MIRT669093 | CDK6 | cyclin dependent kinase 6 | 2 | 2 | ||||||||
MIRT696720 | WNT3 | Wnt family member 3 | 2 | 2 | ||||||||
MIRT698085 | TPM1 | tropomyosin 1 | 2 | 2 | ||||||||
MIRT703284 | GID4 | GID complex subunit 4 homolog | 2 | 2 | ||||||||
MIRT707183 | ARHGEF33 | Rho guanine nucleotide exchange factor 33 | 2 | 2 | ||||||||
MIRT710362 | CREB5 | cAMP responsive element binding protein 5 | 2 | 2 | ||||||||
MIRT713501 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT717153 | LRRC3C | leucine rich repeat containing 3C | 2 | 2 | ||||||||
MIRT719038 | ATP1A1 | ATPase Na+/K+ transporting subunit alpha 1 | 2 | 2 | ||||||||
MIRT719489 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT720284 | DPYSL3 | dihydropyrimidinase like 3 | 2 | 2 | ||||||||
MIRT732474 | NLRP3 | NLR family pyrin domain containing 3 | 2 | 0 | ||||||||
MIRT732620 | MS | multiple sclerosis | 1 | 0 | ||||||||
MIRT732968 | TGFBR2 | transforming growth factor beta receptor 2 | 3 | 0 | ||||||||
MIRT733063 | AGTR1 | angiotensin II receptor type 1 | 3 | 0 | ||||||||
MIRT733206 | ADAM10 | ADAM metallopeptidase domain 10 | 1 | 0 | ||||||||
MIRT733302 | CRP | C-reactive protein | 2 | 0 | ||||||||
MIRT734202 | PDCD4 | programmed cell death 4 | 3 | 0 | ||||||||
MIRT734467 | SIRT1 | sirtuin 1 | 2 | 0 | ||||||||
MIRT734701 | Foxo3 | forkhead box O3 | 1 | 0 | ||||||||
MIRT734889 | SP4 | Sp4 transcription factor | 2 | 0 | ||||||||
MIRT735047 | BATF | basic leucine zipper ATF-like transcription factor | 1 | 0 | ||||||||
MIRT735048 | SPI1 | Spi-1 proto-oncogene | 1 | 0 | ||||||||
MIRT735734 | PICALM | phosphatidylinositol binding clathrin assembly protein | 3 | 0 | ||||||||
MIRT735944 | TNF | tumor necrosis factor | 1 | 0 | ||||||||
MIRT736131 | MYLK | myosin light chain kinase | 2 | 0 | ||||||||
MIRT736780 | FOXP3 | forkhead box P3 | 1 | 0 | ||||||||
MIRT736781 | CEBPB | CCAAT/enhancer binding protein beta | 1 | 0 | ||||||||
MIRT736858 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 0 | ||||||||
MIRT736873 | TLR3 | toll like receptor 3 | 2 | 0 | ||||||||
MIRT736902 | CFH | complement factor H | 2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|